Abstract

Ovarian hyperstimulation syndrome (OHSS) is ovarian enlargement secondary to hormones overstimulating ovarian growth. It can be associated with a spectrum of other clinical findings, including ascites, hemoconcentration, hypercoagulability, and electrolyte imbalances. OHSS most commonly occurs as a complication of treatment with in vitro fertilization medications, such as human chorionic gonadotropin (hCG) or gonadotropin-releasing hormone agonists. OHSS has infrequently been reported to be caused by high hCG levels in complete, partial, or invasive molar pregnancies. The classic signs and symptoms of OHSS include nausea, vomiting, bloating, abdominal pain, tachycardia, tachypnea, and dyspnea. Further positive diagnostic studies for OHSS include enlarged ovaries, ascites, hemoconcentration, hyponatremia, hyperkalemia, and oliguria. OHSS due to molar pregnancies is extremely rare. Suziki et al. performed a literature review in 2014 and describe the eight ever-reported molar pregnancy-associated OHSS cases, three of which were partial molar pregnancies. We present a two-case comparison that first examines an exceptionally rare OHSS case presentation of a 19-year-old female with a partial molar pregnancy that was also complicated by hCG-induced thyrotoxicosis. Following this, we discuss a case of the more classic presentation of OHSS caused by fertility treatments. This case report is of novel interest because we present a case comparison that emphasizes a rare, paradoxical association between OHSS and dilation-evacuation procedures that is important for physicians to be aware of - OHSS is not an adverse event of molar pregnancies that can be eliminated by declining hCG levels after a dilation and evacuation procedure; rather, in a molar pregnancy, OHSS occurs after the dilation and evacuation.

Highlights

  • Ovarian enlargement in the setting of ovarian hyperstimulation syndrome (OHSS) most commonly occurs iatrogenically as an adverse effect of in vitro fertilization (IVF) medications, such as human chorionic gonadotropin or gonadotropin-releasing hormone (GnRH) agonists

  • OHSS has infrequently been reported to be caused by the following etiologies: high human chorionic gonadotropin levels in a multifetal pregnancy, high hCG levels in a complete/partial/invasive molar pregnancy, or hypothyroidism with high thyroid stimulating hormone (TSH) levels acting as hCG [2]

  • We present a two-case comparison that first examines a much rarer OHSS case presentation of a partial molar pregnancy that was complicated by hCG-induced thyrotoxicosis, and we discuss the more classic presentation of OHSS caused by fertility treatments

Read more

Summary

Introduction

Ovarian enlargement in the setting of ovarian hyperstimulation syndrome (OHSS) most commonly occurs iatrogenically as an adverse effect of in vitro fertilization (IVF) medications, such as human chorionic gonadotropin (hCG) or gonadotropin-releasing hormone (GnRH) agonists. On physical exam, she was afebrile, tachycardic (111 beats per minute), normotensive (107/75 mmHg), but in no acute distress. Image A is a coronal computed tomography image and image B is an axial computed tomography image that shows the patient's uterus with bilaterally enlarged cystic ovaries (arrows) and a small amount of fluid in the pelvis (arrowhead) These findings are consistent with the diagnosis of mild grade 2 ovarian hyperstimulation syndrome, as diagnosed on prior ultrasound. The patient was discharged in stable condition with good pain control and instructions to follow up with her obstetrician-gynecologist in one week

Discussion
Conclusions
Disclosures
Nelson SM
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call